IL-17 and -23 Inhibitors for the Treatment of Psoriasis

IL-17 and -23 Inhibitors for the Treatment of Psoriasis

Psoriasis is a chronic inflammatory skin condition with a significant global burden of disease and a wide array of potential treatment options, ranging from topical to systemic therapies. There are currently 11 biologic agents approved by the U.S. Food and Drug Administration (FDA) for the treatmen...

Full description

Bibliographic Details
Main Authors: Sonali Batta, Ramlah Khan, Marcus Zaayman, Allison Limmer, Dario Kivelevitch, Alan Menter
Format: Article
Language:English
Published: European Medical Journal 2023-04-01
Series:European Medical Journal Allergy & Immunology
Online Access:https://www.emjreviews.com/allergy-immunology/article/il-17-and-23-inhibitors-for-the-treatment-of-psoriasis/

Internet

https://www.emjreviews.com/allergy-immunology/article/il-17-and-23-inhibitors-for-the-treatment-of-psoriasis/

Similar Items